Key Highlights
- Arrowhead Pharmaceuticals shares rose 21.67% to $90.67.
- The gain is tied to ongoing positive momentum around the commercial launch of REDEMPLO (plozasiran) for familial chylomicronemia syndrome.
- The company recently received EU marketing authorization for the drug.
- Pipeline updates on cardiometabolic RNAi candidates also supported the move.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares rose 21.67% to $90.67, benefiting from ongoing positive momentum around the commercial launch of REDEMPLO (plozasiran) for familial chylomicronemia syndrome.
What Happened
The stock's gain was supported by accelerating prescriptions and strong early uptake of REDEMPLO.
Recent EU marketing authorization, pipeline updates on cardiometabolic RNAi candidates, and broader biotech interest also supported the sharp gain.
Market Reaction
Shares rose sharply as investors responded to the combination of commercial launch momentum and regulatory progress across the company's pipeline.
Outlook
Continued prescription uptake for REDEMPLO and further updates on the company's cardiometabolic RNAi pipeline are likely to remain key catalysts for the stock going forward.
Why did Arrowhead Pharmaceuticals shares rise 21.67%?
Shares rose on positive momentum around the commercial launch of REDEMPLO (plozasiran) for familial chylomicronemia syndrome, along with recent EU marketing authorization.
What is REDEMPLO?
REDEMPLO (plozasiran) is Arrowhead's treatment for familial chylomicronemia syndrome.
What other pipeline updates supported the stock?
Pipeline updates on cardiometabolic RNAi candidates also supported the gain.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...